Th17 cells play an important role in multiple sclerosis (MS) and its autoimmune model, experimental autoimmune encephalomyelitis (EAE). However, studies have not addressed how enhanced Th17 immune responses can affect demyelinating diseases. We induced EAE with MOG in RORγt transgenic C57BL/6 mice that overexpress a Th17 inducing transcription factor. RORγt transgenic mice developed more severe EAE than wild-type mice with more robust anti-MOG Th17 immune responses. In contrast, mice overexpressing T-bet, a Th1-inducing transcription factor, were resistant to EAE. Therefore, a genetic bias toward Th17 immune responses could contribute to CNS immunopathology.
Introduction
Experimental autoimmune encephalomyelitis (EAE) is widely used as an autoimmune model of multiple sclerosis (MS) (Tsunoda and Fujinami, 1996) . Mice with EAE have inflammatory demyelinating lesions in the central nervous system (CNS) that are histologically similar to MS. Active EAE is mediated by myelin-specific T cells, which are activated in the periphery by sensitization with a CNS antigen and recruited into the CNS. Once in the CNS, they re-encounter the myelin antigen and start the inflammatory process resulting in inflammatory demyelination. In C57BL/6 mice, EAE can be induced by sensitization with myelin oligodendrocyte glycoprotein (MOG), which results in tail and hind limb paralysis (Tsunoda and Fujinami, 1996) . C57BL/6 mice with EAE develop clinical signs that appear around 2 weeks post-induction (p.i.) and begin to subside about 1 month p.i.
Previously, in EAE, the most prominent immune effector cells that have been demonstrated to influence the outcome of disease are T helper (Th)1 and Th2 cells (Martinez et al., 2013) . Th1 cells require the transcription factor T-bet for differentiation, secrete proinflammatory cytokines such as interferon (IFN)-γ, and are thought to play a pathogenic role in EAE (Sato et al., 2011) . Th2 cells can antagonize Th1 cells, secrete anti-inflammatory cytokines, such as interleukin (IL)-4 and IL-10, and play a regulatory role in most types of EAE.
Currently, a newly discovered Th subtype, Th17, has also been implicated to play a pathogenic role in MS and EAE. Th17 cells express the transcription factor retinoic acid-related orphan receptor (ROR)γt and secrete the proinflammatory cytokines IL-17, IL-21, IL-22 and tumor necrosis factor (TNF)-α (Harrington et al., 2006) . In mice, naive CD4 + T cells are differentiated into Th17 cells by priming in the presence of transforming growth factor (TGF)-β and IL-6, which induce their hallmark transcription factor RORγt (Bettelli et al., 2006) , while IL-23 promotes the survival of Th17 cells (Stritesky et al., 2008) . Since the IL-17 receptor and IL-22 receptor are present on a broad range of cell types, Th17 cells can promote a widespread reaction that includes the production of IL-6 and other proinflammatory cytokines. The release of proinflammatory cytokines from Th17 cells can cause immunopathology; dysregulation of Th17 cells has been implicated in many immunemediated diseases ranging from MS to inflammatory bowel disease (IBD) (Ichiyama et al., 2008) . The increased frequency of IL-17-secreting cells in EAE led to the theory that they could be a critical effector cell population of disease. Komiyama et al. first reported attenuation of EAE in IL-17 knockout (KO) mice: the onset of disease was delayed and both the clinical severity and pathological severity of disease were reduced (Komiyama et al., 2006) . Experimentally, the roles of Th cells have been investigated in Journal of Neuroimmunology 276 (2014) 142-149 
